In gemcitabine-resistant cholangiocarcinoma (CCA) cells, curcumin synergistically downregulates the expression of glutaminase (GLS) and glutamine synthetase (GS) by inhibiting LAT2-mediated glutamine (Gln) uptake in conjunction with gemcitabine. This evidence concerns the gene LAT2 and cholangiocarcinoma.